XCT0135908  (Synonyms: XCT)

XCT0135908 (XCT) is a selective Nurr1-RXRα activator with an EC₅₀ value of 0.3 μM in human dopaminergic SH-SY5Y cells. XCT0135908 protects dopaminergic cells against the Parkinson’s disease-related toxin MPP⁺. XCT0135908 can be used for the research of Parkinson’s disease^[1].

XCT0135908 (Compound 7a) (0.5-12.5 μM; overnight) activates the Nurr1-RXRα heterodimer in human dopaminergic SH-SY5Y cells with an EC₅₀ of 0.3 μM^[1].
XCT0135908 (0.5-12.5 μM; 12 h) selectively activates Nurr1-RXRα and Nur77-RXRα heterodimers (but not other RXRα heterodimers or homodimers) in human dopaminergic SH-SY5Y cells, with greater activation of Nur77GAL4-RXRαVP16 than Nurr1GAL4-RXRαVP16^[1].
XCT0135908 (12.5-50 μM) protects mouse Neuro-2a neuroblast cells from MPP⁺-induced toxicity at concentrations of 12.5 μM and 50 μM, with no observed toxicity at 50 μM^[1].
XCT0135908 (0.5-12.5 μM; 24 h) induces a moderate concentration-dependent increase in SREBP-1c expression in human HepG2 hepatic cells, with a maximal ~5-fold increase at 12.5 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

345.40

C₂₁H₁₉N₃O₂

300837-31-4

O=C(O)C1=CC=C(C=C1)NC2=NC(=NC(=C2CC=C)C)C=3C=CC=CC3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Asvos X, et al. BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides. J Med Chem. 2025;68(4):4763-4786.  [Content Brief]